Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000271938 | SCV000338176 | uncertain significance | not provided | 2015-12-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001351448 | SCV001545919 | uncertain significance | X-linked myopathy with postural muscle atrophy | 2024-07-25 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 199 of the FHL1 protein (p.Arg199His). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FHL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 285237). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000271938 | SCV001987968 | uncertain significance | not provided | 2019-11-05 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign in a peer reviewed article to our knowledge |
Ai |
RCV000271938 | SCV002502462 | uncertain significance | not provided | 2021-09-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002356380 | SCV002658353 | uncertain significance | Cardiovascular phenotype | 2024-03-04 | criteria provided, single submitter | clinical testing | The p.R199H variant (also known as c.596G>A), located in coding exon 4 of the FHL1 gene, results from a G to A substitution at nucleotide position 596. The arginine at codon 199 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002502126 | SCV002796310 | uncertain significance | Myopathy, reducing body, X-linked, childhood-onset; Myopathy, reducing body, X-linked, early-onset, severe; X-linked myopathy with postural muscle atrophy; Uruguay Faciocardiomusculoskeletal syndrome; X-linked scapuloperoneal muscular dystrophy | 2021-12-21 | criteria provided, single submitter | clinical testing |